Results 161 to 170 of about 1,181,836 (211)

Likheter mellan CT-P13 och infliximab : En litteraturstudie

, 2020
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Subcutaneous injection of infliximab CT‐P13 results in stable drug levels within 14‐day treatment cycle in Crohn’s disease

Alimentary Pharmacology and Therapeutics, 2022
The new subcutaneous (sc) formulation of the infliximab (IFX) biosimilar CT‐P13 results in homogeneous serum trough concentrations of IFX at steady state.
Xavier Roblin, Stephane Nancey, Stéphane Paul   +2 more
exaly   +2 more sources

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Lancet, The, 2017
BACKGROUND TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but are expensive therapies.
Espen A Haavardsholm, Knut E A Lundin, Jørgen Jahnsen   +2 more
exaly   +2 more sources

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Lancet, The, 2019
BACKGROUND The infliximab biosimilar CT-P13 was approved for use in Crohn's disease after clinical comparison with originator infliximab in ankylosing spondylitis and rheumatoid arthritis; however, concerns about such indication extrapolation have been ...
Beyong Duk Ye, Adi Lahat, Sigal Fishman
exaly   +2 more sources

Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness

Advances in Therapy, 2021
Jae-Hee Cheon, Hyoun Woo Kang, Yun-Jeong Lim   +2 more
exaly   +2 more sources

CT-P13 Subcutaneous Infliximab in Gastroenterology and Rheumatology

Immunotherapy, 2021
The drug infliximab has been a key milestone in the treatment of inflammatory conditions such as Crohn's disease, ulcerative colitis, rheumatoid arthritis and the seronegative spondyloarthritides. Biosimilar drugs followed the originator, further improving access and diversity of therapy choice.
Mai Ahmed, Giulia Bankov, Dan Casey, Martin Edward Perry   +3 more
openaire   +2 more sources

CT-P13 SC for the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology, 2021
Management of Rheumatoid Arthritis (RA) has improved following the implementation of early intensive treat to target recommendations and the availability of different biologicals. Most experience is with TNF blockers, but challenges remain in the efficacy/safety balance, immunogenicity, and long-term drug survival as well as availability and ...
openaire   +2 more sources

Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis

Journal of Clinical Gastroenterology, 2022
Background: We aimed to compare trough infliximab levels and the development of antidrug antibody (ADA) for 1 year between Crohn’s disease (CD) and ulcerative colitis (UC) patients who were biologic-naive, and to evaluate their impact on clinical outcomes.
Kim, Eun Soo, Kim, Sung Kook, Park, Dong Il, Kim, Hyo Jong, Lee, Yoo Jin, Koo, Ja Seol, Kim, Eun Sun, Yoon, Hyuk, Lee, Ji Hyun, Kim, Ji Won, Shin, Sung Jae, Kim, Hyung Wook, Kim, Hyun-Soo, Park, Young Sook, Kim, You Sun, Kim, Tae Oh, Lee, Jun, Choi, Chang Hwan, Han, Dong Soo, Chun, Jaeyoung, Kim, Hyun Soo   +20 more
openaire   +3 more sources

Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU

Clinical Drug Investigation, 2021
CT-P13 (Remsima®; Inflectra®), a biosimilar of reference infliximab (Remicade®), provides a useful alternative for patients requiring infliximab therapy and, as with other biosimilar agents, has the potential to reduce treatment costs. Furthermore, the availability of CT-P13 in a subcutaneous formulation (CT-P13 SC), with the possibility (after ...
openaire   +2 more sources